An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding

Condition:   Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months Intervention:   Drug: Esomezol Cap Sponsor:   Hanmi Pharmaceutical Company Limited Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials